Outcomes of HER2-positive early-stage breast cancer in the trastuzumab era: A population-based study of Canadian patients

Current Oncology

Volumn 20, Issue 6, 2013, Pages

  Zurawska, U ^a   Baribeau, D A ^b   Giilck, S ^c   Victor, C ^d   Gandhi, S ^e   Florescu, A ^a   Verma, S ^e  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^e DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

Adjuvant; HER2 positive breast cancer; Survival; Trastuzumab

Indexed keywords

ANTHRACYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; ARTICLE; BREAST CANCER; CANADA; CANCER GRADING; CANCER STAGING; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MORTALITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RECURRENCE FREE SURVIVAL; RISK; SURVIVAL RATE; TUMOR VOLUME;

EID: 84890026907     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.20.1523     Document Type: Article

References (27)

1. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
2. Prat A, Parker JS, Karginova O, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010;12:R68.
3. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, Mc-Guire WL. Human breast cancer: correlation of relapse and survival with amplification of the her-2/neu oncogene. Science 1987;235:177-82.
4. Panoff JE, Hurley J, Takita C, et al. Risk of locoregional recurrence by receptor status in breast cancer patients receiving modern systemic therapy and post-mastectomy radiation. Breast Cancer Res Treat 2011;128:899-906.
5. Gabos Z, Thoms J, Ghosh S, et al. The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer. Breast Cancer Res Treat 2010;124:187-94.
6. Chen XS, Ma CD, Wu JY, et al. Molecular subtype approximated by quantitative estrogen receptor, progesterone receptor and her2 can predict the prognosis of breast cancer. Tumori 2010;96:103-10.
7. Arvold ND, Taghian AG, Niemierko A, et al. Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J Clin Oncol 2011;29:3885-91.
8. Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 2010;28:1684-91.
9. Cancello G, Maisonneuve P, Rotmensz N, et al. Prognosis in women with small (T1mic, T1a, T1b) node-negative operable breast cancer by immunohistochemically selected subtypes. Breast Cancer Res Treat 2011;127:713-20.
10. O'Brien KM, Cole SR, Tse CK, et al. Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res 2010;16:6100-10.
11. Haque R, Ahmed SA, Inzhakova G, et al. Impact of breast cancer subtypes and treatment on survival: an analysis spanning two decades. Cancer Epidemiol Biomarkers Prev 2012;21:1848-55.
12. Goldenberg MM. Trastuzumab, a recombinant dna-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther 1999;21:309-18.
13. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-her2 monoclonal antibody in women who have her2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-48.
14. Mass RD, Press MF, Anderson S, et al. Evaluation of clinical outcomes according to her2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer 2005;6:240-6.
15. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses her2. N Engl J Med 2001;344:783-92.
16. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of her2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26.
17. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Herceptin Adjuvant (hera) Trial Study Team. Trastuzumab after adjuvant chemotherapy in her2-positive breast cancer. N Engl J Med 2005;353:1659-72.
18. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable her2-positive breast cancer. N Engl J Med 2005;353:1673-84.
19. Slamon D, Eiermann W, Robert N, et al. on behalf of the Breast Cancer International Research Group. Adjuvant trastuzumab in her2-positive breast cancer. N Engl J Med 2011;365:1273-83.
20. Hoffmann-La Roche Limited. Herceptin (Trastuzumab for Infusion) [product monograph]. Mississauga, ON: Hoffmann-La Roche Limited; 2012.
21. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010;28:2784-95. [Erratum in: J Clin Oncol 2010;28:3543]
22. Cancer Care Ontario (cco). Adjuvant to Metastatic Trastuzumab for her2/neu-Overexpressing Breast Cancer [eligibility form]. Toronto, ON: cco; 2013.
23. Onitilo AA, Engel JM, Greenlee RT, Mukesh BN. Breast cancer subtypes based on er/pr and her2 expression: comparison of clinicopathologic features and survival. Clin Med Res 2009;7:4-13.
24. Del Casar JM, Martín A, García C, et al. Characterization of breast cancer subtypes by quantitative assessment of biological parameters: relationship with clinicopathological characteristics, biological features and prognosis. Eur J Obstet Gynecol Reprod Biol 2008;141:147-52.
25. Dawood S, Hu R, Homes MD, et al. Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study. Breast Cancer Res Treat 2011;126:185-92.
26. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295:2492-502.
27. Noonan KL, McCarthy J, Powell E, Laing K, Edwards S, McCrate F. A population-based analysis of patients with early-stage her2-positive breast cancer in Newfoundland and Labrador. Oncol Exch 2012;11:14-19.